Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Pliant Therapeutics, Inc. Common Stock

PLRX

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of integrin-based therapies. The company operates as a single reportable segment focused on developing and commercializing novel integrin-based treatments. Its lead product candidate, PLN-101095, is an oral small molecule targeting integrins for the treatment of solid tumors. The company also advances a pipeline of integrin-based programs across multiple disease areas through its proprietary drug discovery platform.

Last trade $0.6611
Day change -$0.0321 (-4.63%)
Day range $0.656 – $0.717
Volume 549,011
Market cap $43M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$42.77M
Price / earnings
—
Price / book
0.34×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.17×

Profitability

Earnings per share
-$1.46
Return on assets
-53.19%
Return on equity
-71.36%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
8.05×
Quick ratio
8.05×
Cash ratio
1.48×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$66.79M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for PLRX, quarterly periods
Line itemQ3 FY2026 Sep 30, 2026Q2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$7.81M$7.14M$8.19M$7.99M$10.33M$13.39M$15.5M$14.53M
Research and development$17.93M$16.73M$13.58M$15.59M$17.94M$32.2M$43.44M$38.79M
Total operating expenses$25.74M$23.86M$21.77M$23.58M$28.27M$45.59M$58.94M$53.32M
Operating income-$25.74M-$23.86M-$21.77M-$23.58M-$28.27M-$45.59M-$58.94M-$53.32M
Interest expense$0$0$0-$136K-$815K-$809K-$799K-$834K
Income before taxes-$24.38M-$22.37M-$20.04M-$23.58M-$26.3M-$43.3M-$56.17M-$49.73M
Income taxes$0$0$0$0$0$0$0$0
Net income-$24.38M-$22.37M-$20.04M-$23.58M-$26.3M-$43.3M-$56.17M-$49.73M
Net income attributable to common shareholders-$24.38M-$22.37M-$20.04M-$23.58M-$26.3M-$43.3M-$56.17M-$49.73M
EBITDA-$25.51M-$23.61M-$21.51M-$23.21M-$27.83M-$45.15M-$58.49M-$52.86M
Basic earnings per share-$0.39-$0.36-$0.32-$0.38-$0.43-$0.71-$0.92-$0.82
Diluted earnings per share-$0.39-$0.36-$0.32-$0.38-$0.43-$0.71-$0.92-$0.82

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

Pliant Therapeutics presented updated Phase 1 trial data for PLN-101095, an integrin inhibitor combined with pembrolizumab, showing encouraging results in immune checkpoint inhibitor-refractory patients. The drug demonstrated confirmed responses with 89% average tumor reduction and 19-month median time on treatment. The company has initiated a Phase 1b expansion trial with interim data expected in 2027.

Investing.com

Pliant Therapeutics CBO sells shares worth over $114k - Investing.com

Pliant Therapeutics' Chief Business Officer Hans Hull sold 9,900 shares of the company's common stock, valued at over $114,000. The sale was part of a nondiscretionary plan to satisfy withholding tax liabilities related to the vesting of performance-vested stock units.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily

No stock split records found.